Advocacy

Awareness

Education

Research

ResearchStaff Update
PKDF Chief Science Officer Dr. David Baron co-authors new paper with FDA and top nephrologists

PKDF Chief Science Officer Dr. David Baron co-authors new paper with FDA and top nephrologists

Only a few new drugs for chronic kidney disease (CKD) have been approved in the last several decades because drug companies have shied away from the renal “space.” The need for novel therapies for CKD is compelling, especially because they might mitigate the need...

Research
How motherhood inspired PKD patient to get involved with tolvaptan clinical trials

How motherhood inspired PKD patient to get involved with tolvaptan clinical trials

This Mother’s Day, we’re celebrating moms and major milestones. We reached out to Jullie Hoggan, who took part in the clinical trials that led to the approval of tolvaptan, to learn more about what having this treatment means to her and her family: The day I became...

Research
PKD Foundation Chief Scientific Officer’s take on FDA-approved treatment as a PKD patient

PKD Foundation Chief Scientific Officer’s take on FDA-approved treatment as a PKD patient

Our very own Dr. David Baron shares his personal background with PKD, his journey joining the Foundation and his thoughts on the exciting news about the new treatment for ADPKD:   Little did I know when I was studying the effects of vasopressin and its...